BMY Bristol-Myers Squibb
- Official Name: BRISTOL-MYERS SQUIBB CO
- Headquarters: Route 206 And Province Line Road, PRINCETON, NJ, 08543 US
- CEO: Christopher S. Boerner
- Website: bms.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 3.518 | 0.935 - (2.583) | ||
| 2025-07-15 | 1R | Won by 1.377 | (1.410) - (2.787) | ||
| 2025-07-21 | 2 | Lost by 6.952 | (0.271) - 6.681 | ||
| 2025-07-23 | 1R | Lost by 2.971 | 1.577 - 4.548 | ||
| 2025-07-28 | 3 | Won by 2.485 | 2.169 - (0.316) | ||
| 2025-07-29 | 2R | Lost by 6.258 | (3.655) - 2.603 | ||
| 2025-08-04 | 4 | Won by 1.256 | (2.888) - (4.144) | ||
| 2025-08-07 | 1R | Won by 0.590 | 1.610 - 1.020 | ||
| 2025-08-11 | 5 | Won by 2.906 | 2.191 - (0.715) | ||
| 2025-08-18 | 6 | Won by 3.580 | 4.581 - 1.001 | ||
| 2025-08-21 | 2R | Won by 2.213 | 0.522 - (1.691) | ||
| 2025-08-25 | 7 | Lost by 7.313 | (3.043) - 4.270 | ||
| 2025-09-01 | 8 | Won by 0.001 | 0.115 - 0.114 | ||
| 2025-09-04 | 3R | Lost by 5.040 | (1.732) - 3.308 | ||
| 2025-09-08 | 9 | Lost by 2.939 | (1.084) - 1.855 | ||
| 2025-09-15 | 10 | Won by 3.970 | (0.840) - (4.810) | ||
| 2025-09-22 | 11 | Lost by 2.547 | (2.603) - (0.056) | ||
| 2025-09-29 | 12 | Lost by 0.177 | (1.649) - (1.472) | ||
| 2025-10-06 | 13 | Won by 6.147 | 1.608 - (4.539) | ||
| 2025-10-13 | 14 | Won by 0.803 | (3.306) - (4.109) | ||
| 2025-10-20 | 15 | Lost by 2.707 | 0.119 - 2.826 |
Latest News

Can You Still Buy Merck Stock Today?
For questions about this article or underlying research, email help@trefis.com.

While pharma peers stumble, AbbVie defeated the patent cliff
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Xenon Pharmaceuticals Q3 Earnings Call Highlights
Xenon Pharmaceuticals (NASDAQ:XENE) expects pivotal depression study results in December, earlier than previously projected, while preparing for a pot...

Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data
Bristol-Myers Squibb (NYSE:BMY) reported new 56-week Phase 3 data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy. The updated result...

5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names pr...

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potent...

What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
For questions about this article or underlying research, email help@trefis.com.

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Bristol Myers Squibb has a 4% yield and a 55% payout ratio, which should greatly interest dividend lovers.

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.

What Could Stall AbbVie Stock's Run?
For questions about this article or underlying research, email help@trefis.com.

Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Bristol-Myers Squibb (BMY) said late Friday that 56-week results from its Phase 3 SCOUT-HCM clinical

Better Dividend Stock: Bristol Myers Squibb vs. AbbVie
Key TakeawaysBristol Myers Squibb yields 4. 1% and AbbVie 2.

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
PRINCETON, N.J., November 06, 2026--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic...

Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristo...

3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market
They are so much more than just dividend stocks.
Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions
With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the fi...

The One Thing To Settle Before Buying AbbVie Stock
For questions about this article or underlying research, email help@trefis.com.

Bristol Myers Squibb (BMY) Expands Neuroscience Push With Multi Year AI Alliance
Bristol Myers Squibb (NYSE:BMY) has entered a multi-year collaboration with Pathos AI and Tempus AI focused on neuroscience. The alliance aims to buil...

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
Halozyme Therapeutics (NASDAQ:HALO) raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in...

What Are Amgen Investors Betting On?
For questions about this article or underlying research, email help@trefis.com.

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In?
Bristol-Myers Squibb (BMY) is back in the spotlight after the FDA granted accelerated approval for ZENBEXUS in multiple myeloma, along with fresh posi...